851 Voyager V1 (VV1) oncolytic virus combined with immune checkpoint therapy boosts CTL responses to multiple tumor antigens and correspondingly deepens tumor responses in murine models of melanoma, lung and colon cancer

Authors :: Priyanka Ram
Navpreet Tung
Himani Sharma
Ben Fulton
Kah-Whye Peng
Stephen Russell
Markus Mohrs
Gavin Thurston
Christos Kyratsous
Alina Baum
Jessica Kirshner
John Lin
Saida Dadi-Mehmetaj
Source :: Regular and Young Investigator Award Abstracts.
Publication Year :: 2022
Publisher :: BMJ Publishing Group Ltd, 2022.

Tools